BEIJING, June 1 (Xinhua) — A China-developed intranasal vaccine against COVID-19 has shown to be safe and effective in early-stage human trials, according to a new study published in the journal The Lancet Respiratory Medicine.
Compared with currently available COVID-19 vaccines that are administered by intramuscular injection, the new drug, coded dNS1-RBD, is a two-dose, live-attenuated influenza vaccine given